Cambrex Manufacturing Facility Completes Successful US FDA Pre-Approval Inspection

Cambrex's picture
Printer-friendly versionPrinter-friendly version

Contact Cambrex

Stephanie Harrison

.(JavaScript must be enabled to view this email address)

East Rutherford, NJ –  Cambrex Corporation (NYSE: CBM, "Cambrex") announced that the US Food and Drug Administration (FDA) completed an inspection of Cambrex’s active pharmaceutical ingredient (API) manufacturing facility in Charles City, Iowa. The Pre-Approval Inspection (PAI), conducted in February 2014 for a new API, found the site to be compliant with the principles and guidelines of Good Manufacturing Practice (GMP) and there were no Form 483 observations issued.

Once again, we are extremely happy with the result of this FDA inspection. Our customers continue to be impressed with our commitment to quality and our exceptional regulatory compliance track record,” remarked Joe Nettleton, VP of Operations and Site Director for Cambrex Charles City.

The entire facility and the quality systems used for the manufacture and release of APIs, drug product intermediates, and food grade products were subject to a detailed compliance inspection by the US FDA. This inspection follows successful PAI and GMP inspections by the US FDA at Cambrex Charles City in July 2013 and February 2012, neither of which resulted in any Form 483 observations, and the KFDA (Korea) in January 2012 and the MHRA (UK) in October 2011.

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit

Copy this html code to your website/blog to embed this press release.


Post new comment

1 + 1 =

To prevent automated spam submissions leave this field empty.